Enterovirus A71 (EV-A71) is associated with neurological conditions such as acute meningitis and encephalitis. The virus is detected in the bloodstream, and high blood viral loads are associated with central nervous system (CNS) manifestations. We used an in vitro blood–brain barrier (BBB) model made up of human brain-like endothelial cells (hBLECs) and brain pericytes grown in transwell systems to investigate whether three genetically distinct EV-A71 strains (subgenogroups C1, C1-like, and C4) can cross the human BBB. EV-A71 poorly replicated in hBLECs, which released moderate amounts of infectious viruses from their luminal side and trace amounts of infectious viruses from their basolateral side. The barrier properties of hBLECs were not impaired by EV-A71 infection. We investigated the passage through hBLECs of EV-A71-infected white blood cells. EV-A71 strains efficiently replicated in immune cells, including monocytes, neutrophils, and NK/T cells. Attachment to hBLECs of immune cells infected with the C1-like virus was higher than attachment of cells infected with C1-06. EV-A71 infection did not impair the transmigration of immune cells through hBLECs. Overall, EV-A71 targets different white blood cell populations that have the potential to be used as a Trojan horse to cross hBLECs more efficiently than cell-free EV-A71 particles. IMPORTANCE: Enterovirus A71 (EV-A71) was first reported in the USA, and numerous outbreaks have since occurred in Asia and Europe. EV-A71 re-emerged as a new multirecombinant strain in 2015 in Europe and is now widespread. The virus causes hand-foot-and-mouth disease in young children and is involved in nervous system infections. How the virus spreads to the nervous system is unclear. We investigated whether white blood cells could be infected by EV-A71 and transmit it across human endothelial cells mimicking the blood–brain barrier protecting the brain from adverse effects. We found that endothelial cells provide a strong roadblock to prevent the passage of free virus particles but allow the migration of infected immune cells, including monocytes, neutrophils, and NK/T cells. Our data are consistent with the potential role of immune cells in the pathogenesis of EV-A71 infections by spreading the virus in the blood and across the human blood–brain barrier.
The emergence of new strains in RNA viruses is mainly due to mutations or intra and inter-genotype homologous recombination. Non-homologous recombinations may be deleterious and are rarely detected. In previous studies, we identified HCV-1b strains bearing two tandemly repeated V3 regions in the NS5A gene without ORF disruption. This polymorphism may be associated with an unfavorable course of liver disease and possibly involved in liver carcinogenesis. Here we aimed at characterizing the origin of these mutant strains and identifying the evolutionary mechanism on which the V3 duplication relies. Direct sequencing of the entire NS5A and E1 genes was performed on 27 mutant strains. Quasispecies analyses in consecutive samples were also performed by cloning and sequencing the NS5A gene for all mutant and wild strains. We analyzed the mutant and wild-type sequence polymorphisms using Bayesian methods to infer the evolutionary history of and the molecular mechanism leading to the duplication-like event. Quasispecies were entirely composed of exclusively mutant or wild-type strains respectively. Mutant quasispecies were found to have been present since contamination and had persisted for at least 10 years. This V3 duplication-like event appears to have resulted from non-homologous recombination between HCV-1b wild-type strains around 100 years ago. The association between increased liver disease severity and these HCV-1b mutants may explain their persistence in chronically infected patients. These results emphasize the possible consequences of non-homologous recombination in the emergence and severity of new viral diseases.
Introduction: Rare enterovirus types assigned to species C (EV-C) display respiratory tropism and may be associated with neurological involvement, which display similarities to EV-D68 disease.Patients and methods: We conducted continuous enterovirus/rhinovirus (RV) surveillance between 2013 and 2025, including systematic EV/RV screening of all respiratory samples and reflex VP4/VP2 sequencing (a total of 5,855 samples). When an EV-C strain was detected, the VP1-coding and complete genome sequence was sequenced to investigate phylogenetic relationships and to identify any recombinant forms, respectively.Results: Over the 13‑year period, 30 EV‑C infections were identified from respiratory samples, with 23 cases (77%) detected between 2013 and 2018. EV‑C105 was the most frequent type (n=11), followed by EV‑C104 (n=8), EV‑C109 (n=6), and EV‑C117 (n=5). We also document the first detection of EV‑C117 in France and only the second case reported in Europe since its initial description in 2011 in Lithuania. Clinical data were available for 25 patients, of whom 19 (76%) were children. Respiratory symptoms predominated (17/25, 68%), and 7 patients presented with lower respiratory tract infections. Hospitalization was required in 18 cases (72%), including three with ICU admissions (12%). Nearly half of the patients (12/25, 48%) had at least one risk factor for severe respiratory disease. Across all respiratory EV‑C types, recovered sequences clustered with contemporary global strains.Conclusions: This long‑term surveillance highlights the sustained circulation of multiple respiratory EV‑C types in France and underscores the need for continued clinical and genomic monitoring to assess the evolution and pathogenic potential of these enteroviruses.
BACKGROUND: Enteroviruses (EV)-A71 and EV-D68 are potentially associated with severe clinical conditions, especially in infants and young children. Population susceptibility to these viruses is unknown in France. AIM: We sought to estimate seroprevalence of EV-A71 and EV-D68 neutralising antibodies (nAbs) among children and adolescents living in France. METHODS: A stratified sampling approach based on sex, age and geographical area of residence was applied to obtain sera for routine diagnostic from ˂ 18-year-olds in metropolitan France. A total of 501 serum samples collected between 2023 and 2025 from 0–17-year-olds were included in the investigation. Neutralising activity was tested against EV-A71 sub-genogroup C1 and EV-D68 subclade B3 strains isolated in 2016, allowing to determine seropositivity and nAb titre. Data were analysed overall, by sex, age group and geographical area. RESULTS: For EV-A71, the overall estimated seroprevalence was 43.7% (95% CI: 39.3−48.2) while for EV-D68 this reached 96.0% (95% CI: 93.9–97.5). No differences according to sex were observed. Unlike EV-D68, EV-A71 seropositivity rate varied significantly by age group (p = 0.002) and area of residence (p < 0.001). Notably, 23 of 25 children aged ˂ 1 year lacked EV-A71 protective antibodies. Concerning nAb titres, significant differences occurred across age groups both for EV-A71 (p = 0.004) and EV-D68 (p < 0.001). The nAb titres appeared as highest in 1 to under-2-year-olds for EV-A71 and 0 to under-1-year-olds for EV-D68. CONCLUSION: This seroprevalence study in France reveals a high proportion of newborns and infants susceptible to EV-A71 at potential risk of severe disease, contrasting with the high level of immunity against EV-D68 across all paediatric age groups.